| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology |
From the Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine (Y.L., S.T., Y.A., M.A., Y.S., T.M., H.A., S.S., H.O., M.H.) and Cardiovascular Division of Internal Medicine, National Cardiovascular Center (A.O., J.K., H.T., M.K.), Osaka, Japan.
Correspondence to Masafumi Kitakaze, Cardiovascular Division of Internal Medicine, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka, 565-8565, Japan. E-mail kitakaze{at}zf6.so-net.ne.jp
Sympathomimetic stimulation, angiotensin II, or endothelin-1 is considered to be an essential stimulus mediating ventricular hypertrophy. Adenosine is known to protect the heart from excessive catecholamine exposure, reduce production of endothelin-1, and attenuate the activation of the renin-angiotensin system. These findings suggest that adenosine may also attenuate myocardial hypertrophy. To verify this hypothesis, we examined whether activation of adenosine receptors can attenuate cardiac hypertrophy and reduce the risk of heart failure. Our in vitro study of neonatal rat cardiomyocytes showed that 2-chloroadenosine (CADO), a stable adenosine analogue, inhibits protein synthesis of cardiomyocytes induced by phenylephrine, endothelin-1, angiotensin II, or isoproterenol, which were mimicked by the stimulation of adenosine A1 receptors. For our in vivo study, cardiac hypertrophy was induced by transverse aortic constriction (TAC) in C57BL/6 male mice. Four weeks after TAC, both heart to body weight ratio (6.80±0.18 versus 8.34±0.33 mg/g, P<0.0001) as well as lung to body weight ratio (6.23±0.27 versus 10.03±0.85 mg/g, P<0.0001) became significantly lower in CADO-treated mice than in the TAC group. Left ventricular fractional shortening and left ventricular dP/dtmax were improved significantly by CADO treatment. Similar results were obtained using the selective adenosine A1 agonist N6-cyclopentyladenosine (CPA). A nonselective adenosine antagonist, 8-(p-sulfophenyl)-theophylline, and a selective adenosine A1 antagonist, 8-cyclopentyl-1,3-dipropylxanthine, eliminated the antihypertrophic effect of CADO and CPA, respectively. The plasma norepinephrine level was decreased and myocardial expression of regulator of G protein signaling 4 was upregulated in CADO-treated mice. These results indicate that the stimulation of adenosine receptors attenuates both the cardiac hypertrophy and myocardial dysfunction via adenosine A1 receptormediated mechanisms.
Key Words: adenosine cardiomyopathy echocardiography heart failure myocytes
This article has been cited by other articles:
![]() |
J. T. Fassett, X. Xu, X. Hu, G. Zhu, J. French, Y. Chen, and R. J. Bache Adenosine regulation of microtubule dynamics in cardiac hypertrophy Am J Physiol Heart Circ Physiol, August 1, 2009; 297(2): H523 - H532. [Abstract] [Full Text] [PDF] |
||||
![]() |
F Franceschi, J-C Deharo, R Giorgi, Y By, C Monserrat, J Condo, Z Ibrahim, A Saadjian, and R Guieu Peripheral plasma adenosine release in patients with chronic heart failure Heart, April 1, 2009; 95(8): 651 - 655. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ai, W. Pang, N. Li, M. Xu, P. D. Jones, J. Yang, Y. Zhang, N. Chiamvimonvat, J. Y.-J. Shyy, B. D. Hammock, et al. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy PNAS, January 13, 2009; 106(2): 564 - 569. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Rothermel and J. A. Hill Adenosine A3 Receptor and Cardioprotection: Enticing, Enigmatic, Elusive Circulation, October 21, 2008; 118(17): 1691 - 1693. [Full Text] [PDF] |
||||
![]() |
Z. Lu, J. Fassett, X. Xu, X. Hu, G. Zhu, J. French, P. Zhang, J. Schnermann, R. J. Bache, and Y. Chen Adenosine A3 Receptor Deficiency Exerts Unanticipated Protective Effects on the Pressure-Overloaded Left Ventricle Circulation, October 21, 2008; 118(17): 1713 - 1721. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Xu, J. Fassett, X. Hu, G. Zhu, Z. Lu, Y. Li, J. Schnermann, R. J. Bache, and Y. Chen Ecto-5'-Nucleotidase Deficiency Exacerbates Pressure-Overload-Induced Left Ventricular Hypertrophy and Dysfunction Hypertension, June 1, 2008; 51(6): 1557 - 1564. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Schulz and G. Heusch Extracellular Adenosine Attenuates Left Ventricular Hypertrophy Through Its Impact on the Protein Kinase and Phosphatase Interaction Hypertension, June 1, 2008; 51(6): 1474 - 1475. [Full Text] [PDF] |
||||
![]() |
V. Vallon, C. Miracle, and S. Thomson Adenosine and kidney function: Potential implications in patients with heart failure Eur J Heart Fail, February 1, 2008; 10(2): 176 - 187. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. De Luca, A. Mebazaa, G. Filippatos, J. T. Parissis, M. Bohm, A. A. Voors, M. Nieminen, F. Zannad, A. Rhodes, A. El-Banayosy, et al. Overview of emerging pharmacologic agents for acute heart failure syndromes Eur J Heart Fail, February 1, 2008; 10(2): 201 - 213. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Givertz, B. M. Massie, T. K. Fields, L. L. Pearson, H. C. Dittrich, and on behalf of the CKI-201 and CKI-202 Investigators The Effects of KW-3902, an Adenosine A1-Receptor Antagonist,on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure and Renal Impairment or Diuretic Resistance J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1551 - 1560. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-M. Lee, M.-S. Lin, and N.-C. Chang Inhibition of histone deacetylase on ventricular remodeling in infarcted rats Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H968 - H977. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Funakoshi, L. C. Zacharia, Z. Tang, J. Zhang, L. L. Lee, J. C. Good, D. E. Herrmann, Y. Higuchi, W. J. Koch, E. K. Jackson, et al. A1 Adenosine Receptor Upregulation Accompanies Decreasing Myocardial Adenosine Levels in Mice With Left Ventricular Dysfunction Circulation, May 1, 2007; 115(17): 2307 - 2315. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xia, S. Javadov, T. X. Gan, T. Pang, M. A. Cook, and M. Karmazyn Distinct KATP Channels Mediate the Antihypertrophic Effects of Adenosine Receptor Activation in Neonatal Rat Ventricular Myocytes J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 14 - 21. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. deGoma, R. H. Vagelos, M. B. Fowler, and E. A. Ashley Emerging Therapies for the Management of Decompensated Heart Failure: From Bench to Bedside J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2397 - 2409. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Funakoshi, T. O. Chan, J. C. Good, J. R. Libonati, J. Piuhola, X. Chen, S. M. MacDonnell, L. L. Lee, D. E. Herrmann, J. Zhang, et al. Regulated Overexpression of the A1-Adenosine Receptor in Mice Results in Adverse but Reversible Changes in Cardiac Morphology and Function Circulation, November 21, 2006; 114(21): 2240 - 2250. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wakeno, T. Minamino, O. Seguchi, H. Okazaki, O. Tsukamoto, K.-i. Okada, A. Hirata, M. Fujita, H. Asanuma, J. Kim, et al. Long-Term Stimulation of Adenosine A2b Receptors Begun After Myocardial Infarction Prevents Cardiac Remodeling in Rats Circulation, October 31, 2006; 114(18): 1923 - 1932. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Dickhout and R. C. Austin Proteasomal Regulation of Cardiac Hypertrophy: Is Demolition Necessary for Building? Circulation, October 24, 2006; 114(17): 1796 - 1798. [Full Text] [PDF] |
||||
![]() |
M. Podgorska, K. Kocbuch, M. Grden, A. Szutowicz, and T. Pawelczyk Reduced ability to release adenosine by diabetic rat cardiac fibroblasts due to altered expression of nucleoside transporters J. Physiol., October 1, 2006; 576(1): 179 - 189. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Synowitz, R. Glass, K. Farber, D. Markovic, G. Kronenberg, K. Herrmann, J. Schnermann, C. Nolte, N. van Rooijen, J. Kiwit, et al. A1 Adenosine Receptors in Microglia Control Glioblastoma-Host Interaction. Cancer Res., September 1, 2006; 66(17): 8550 - 8557. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liao, S. Takashima, H. Zhao, Y. Asano, Y. Shintani, T. Minamino, J. Kim, M. Fujita, M. Hori, and M. Kitakaze Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice Cardiovasc Res, April 1, 2006; 70(1): 107 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yamamoto, M. Ohishi, T. Katsuya, N. Ito, M. Ikushima, M. Kaibe, Y. Tatara, A. Shiota, S. Sugano, S. Takeda, et al. Deletion of Angiotensin-Converting Enzyme 2 Accelerates Pressure Overload-Induced Cardiac Dysfunction by Increasing Local Angiotensin II Hypertension, April 1, 2006; 47(4): 718 - 726. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yuan, C. Cao, J. H. Han, S. Z. Kim, and S. H. Kim Adenosine-Stimulated Atrial Natriuretic Peptide Release Through A1 Receptor Subtype Hypertension, December 1, 2005; 46(6): 1381 - 1387. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liao, S. Takashima, N. Maeda, N. Ouchi, K. Komamura, I. Shimomura, M. Hori, Y. Matsuzawa, T. Funahashi, and M. Kitakaze Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism Cardiovasc Res, September 1, 2005; 67(4): 705 - 713. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liao, M. Asakura, S. Takashima, A. Ogai, Y. Asano, H. Asanuma, T. Minamino, H. Tomoike, M. Hori, and M. Kitakaze Benidipine, a long-acting calcium channel blocker, inhibits cardiac remodeling in pressure-overloaded mice Cardiovasc Res, March 1, 2005; 65(4): 879 - 888. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Reichelt, L. Willems, J. G. Molina, C.-X. Sun, J. C. Noble, K. J. Ashton, J. Schnermann, M. R. Blackburn, and J. P. Headrick Genetic Deletion of the A1 Adenosine Receptor Limits Myocardial Ischemic Tolerance Circ. Res., February 18, 2005; 96(3): 363 - 367. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. T. Gan, V. Rajapurohitam, J. V. Haist, P. Chidiac, M. A. Cook, and M. Karmazyn Inhibition of Phenylephrine-Induced Cardiomyocyte Hypertrophy by Activation of Multiple Adenosine Receptor Subtypes J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 27 - 34. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E Hardt and J. Sadoshima Negative regulators of cardiac hypertrophy Cardiovasc Res, August 15, 2004; 63(3): 500 - 509. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liao, M. Asakura, S. Takashima, A. Ogai, Y. Asano, Y. Shintani, T. Minamino, H. Asanuma, S. Sanada, J. Kim, et al. Celiprolol, A Vasodilatory {beta}-Blocker, Inhibits Pressure Overload-Induced Cardiac Hypertrophy and Prevents the Transition to Heart Failure via Nitric Oxide-Dependent Mechanisms in Mice Circulation, August 10, 2004; 110(6): 692 - 699. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chen and R. J. Bache Adenosine: A Modulator of the Cardiac Response to Stress Circ. Res., October 17, 2003; 93(8): 691 - 693. [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |